Alvotech (ALVO)

NASDAQ: ALVO · IEX Real-Time Price · USD
7.42
+0.09 (1.23%)
Aug 8, 2022 4:30 PM EDT - Market closed

Company Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.

It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product.

The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Alvotech
Country Iceland
Founded 2013
Industry Drug Manufacturers-Specialty & Generic
Sector Health Care
Employees 784

Contact Details

Address:
Saemundargata 15-19
Reykjavik 102
Iceland
Phone 354 422 4500

Stock Details

Ticker Symbol ALVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1898416
SIC Code 2836

Key Executives

Name Position
Robert Wessman Founder and Executive Chairman of Directors
Mark Levick Chief Executive Officer
Joel Morales Chief Financial Officer
Sean Gaskell Chief Technical Officer
Joseph E. McClellan Chief Scientific Officer
Sigridur Elin Gudlaugsdottir Vice President of Human Resources
Tanya Zharov Deputy Chief Executive Officer
Reem Malki Chief Quality Officer
Anil Okay Chief Commercial Officer
Ming Li Chief Strategy Officer

Latest SEC Filings

Date Type Title
Jul 27, 2022 F-1/A Registration statement for certain foreign private issuers
Jul 22, 2022 F-1 Registration statement for certain foreign private issuers
Jul 20, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jul 18, 2022 SC 13D/A General statement of acquisition of beneficial ownership
Jul 18, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jul 15, 2022 SC 13D/A General statement of acquisition of beneficial ownership
Jul 14, 2022 F-1 Registration statement for certain foreign private issuers
Jul 13, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jul 7, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jul 5, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]